Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
C1 esterase inhibitor (human)
|
| gptkbp:approvalYear |
2008
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B06AC01
|
| gptkbp:brand |
C1 esterase inhibitor (human)
|
| gptkbp:form |
lyophilized powder for reconstitution
|
| gptkbp:halfLife |
56 hours
|
| gptkbp:indication |
prevention of hereditary angioedema attacks
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:mechanismOfAction |
C1 esterase inhibitor replacement
|
| gptkbp:origin |
human plasma
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea headache rash |
| gptkbp:storage |
2-25°C
|
| gptkbp:usedFor |
gptkb:hereditary_hemorrhagic_telangiectasia
|
| gptkbp:bfsParent |
gptkb:Takeda_(in_Japan)
gptkb:C1_esterase_inhibitor gptkb:Shire_plc gptkb:Shire_(acquired) |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cinryze
|